Sponsor or institution
Clinical trials and research at Shanghai AbelZeta Ltd.
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Shanghai AbelZeta Ltd. that are recruiting, in China. By phase: Phase 1/2 (2), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| C-CAR031 CAR T-cell infusion for GPC3-positive advanced squamous cell lung cancer | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Mar 2, 2026 |
| A-CAR032 CAR-T therapy for metastatic castration-resistant prostate cancer | Phase 1 | Beijing, Beijing Municipality and 3 other locations | Recruiting | Jan 15, 2026 |
| Evaluating Prizloncabtagene Autoleucel for patients with relapsed/refractory large B-cell lymphoma | Phase 1/2 | Beijing and 14 other locations | Recruiting | Apr 6, 2023 |
| Evaluating C-CAR088 for patients with relapsed or refractory multiple myeloma | Phase 1/2 | Tianjin | Recruiting | Aug 30, 2022 |
All recruiting trials (4)
-
C-CAR031 CAR T-cell infusion for GPC3-positive advanced squamous cell lung cancer
This trial will test a CAR T-cell infusion called C-CAR031 in adults with GPC3-positive advanced or metastatic squamous cell lung cancer who have progressed on or cannot tolerate up to three prior systemic treatments.
-
A-CAR032 CAR-T therapy for metastatic castration-resistant prostate cancer
This early-phase treatment will try A-CAR032, a CAR-T cell therapy, in adults with metastatic castration‑resistant prostate cancer who progressed after ARPI and are not eligible for standard treatment.
-
Evaluating Prizloncabtagene Autoleucel for patients with relapsed/refractory large B-cell lymphoma
This study is testing a new treatment called Prizloncabtagene Autoleucel to see if it can help people with relapsed or hard-to-treat large B-cell lymphoma.
-
Evaluating C-CAR088 for patients with relapsed or refractory multiple myeloma
This study is testing a new CAR-T cell therapy called C-CAR088 to see if it can help people with relapsed or refractory multiple myeloma feel better.
Quick answers
How many clinical trials run by Shanghai AbelZeta Ltd. are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.